PT-141 (Bremelanotide) and Alcohol: What You Need to Know Before You Drink
HealthRX.com
Alcohol did not change bremelanotide levels in one study
Key numbers
- 0.6 g/kgAlcohol dose in the label's study; it did not change bremelanotide blood levelsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 40.0%Nausea rate with Vyleesi in pooled phase 3 trials, versus 1.3% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 6 mmHgMaximal systolic blood pressure rise after a Vyleesi dose; diastolic rise was 3 mmHgSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 45 minutesMinimum time before anticipated sexual activity to take a Vyleesi doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
From the public record
Bremelanotide and alcohol use: one human crossover trial
Single intranasal doses of bremelanotide with or without ethanol were found safe and generally well tolerated in Clayton 2017, a randomized crossover trial of 24 healthy men and women. The same study found no clinically significant pharmacokinetic interaction between ethanol and bremelanotide overall.
| Measure | Value | Note |
|---|---|---|
| Human: Clayton 2017, randomized crossover trial, 24 healthy men and women | safe and generally well tolerated | Intranasal single doses, with or without ethanol, were found safe and generally well tolerated. PMID 28189361 |
| Human: Clayton 2017, blood pressure | no significant drug-related hypotension | Intranasal BMT: no significant drug-related hypotensive or orthostatic hypotensive effects. PMID 28189361 |
| Human: Clayton 2017, pharmacokinetic interaction | no clinically significant interaction | Intranasal BMT: no clinically significant pharmacokinetic interactions with ethanol, overall. PMID 28189361 |
How this was calculated
PubMed title and abstract search on 2026-11-13 for bremelanotide, PT-141, PT 141 with alcohol, alcohol consumption, alcohol intake, alcoholic beverages: 3 records, 3 abstracts read, 1 study listed in 3 rows, each row summarising its own abstract.
Bremelanotide and alcohol use: 1 human, 0 animal and 0 laboratory studies of 3 PubMed records.
At a glance
- Approved product and use / Vyleesi 1.75 mg subcutaneous for premenopausal women with acquired, generalized HSDD [1]
- Dosing / at least 45 minutes before anticipated sexual activity; no more than one dose in 24 hours; more than 8 doses per month is not recommended [1]
- Alcohol study / 24 healthy volunteers; alcohol 0.6 g/kg did not change bremelanotide levels; 20 mg intranasal dose [1]
- Flushing and headache / combination rates similar to the higher single-agent rate [1]
- Nausea in phase 3 / 40.0% with Vyleesi vs 1.3% with placebo [1]
- Blood pressure / maximal rise 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after a dose [1]
- Oral naltrexone / Vyleesi may significantly decrease oral naltrexone exposure; the label says to avoid combining them when naltrexone is used to treat alcohol or opioid addiction [1]
What did the alcohol study find?
The Vyleesi label describes a placebo-controlled, randomized, double-blind crossover study in 24 healthy volunteers [1]. Alcohol was given at 0.6 g/kg. It did not change bremelanotide blood levels, and flushing and headache rates when the two were combined were similar to the higher of the two single-agent rates [1].
The study used a 20 mg intranasal dose, about 2.5-fold the Cmax of Vyleesi, not the approved 1.75 mg subcutaneous injection [1]. Vyleesi itself is used as needed at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours [1].
Questions worth asking
What about nausea, flushing and headache?
Nausea is the most common adverse reaction with Vyleesi. In the pooled phase 3 trials, nausea occurred in 40.0% of Vyleesi-treated women versus 1.3% on placebo [1]. It was highest after the first dose, reported in 21% of patients, and fell to about 3% after later doses [1]. Thirteen percent received an anti-nausea medicine, and 8% stopped the trials because of nausea [1].
Flushing occurred in 20.3% versus 0.3% on placebo, and headache in 11.3% versus 1.9% [1].
Pre-treatment with oral ondansetron did not reduce Vyleesi-associated nausea. In a phase 4 study, 228 healthy women received 8 mg ondansetron or placebo 30 minutes before a single 1.75 mg dose, and there was no significant difference in nausea [1]. The label says this pre-treatment is not recommended [1].
How does Vyleesi affect blood pressure?
Vyleesi transiently raises blood pressure and lowers heart rate after each dose [1]. The label reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate reduced by up to 5 beats per minute; values usually returned to baseline within 12 hours [1]. Those are maximal figures, not average ones.
In a separate open-label ambulatory study of 127 premenopausal women who took Vyleesi once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic and 1.7 mmHg diastolic, with a mean heart rate decrease of 0.5 beats per minute [1]. Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [1].
For context, a meta-analysis of 36 trials with 2,865 participants found that reducing alcohol intake lowered blood pressure most in people who drank six or more drinks per day and cut intake by about half [2]. The label's alcohol study, as summarized above, does not report a blood pressure result for the combination.
The naltrexone interaction is the alcohol-related label warning
If the alcohol question is really about alcohol use disorder treatment, the label has a specific interaction. Vyleesi may significantly decrease the systemic exposure of orally administered naltrexone, and the label says to avoid Vyleesi with oral naltrexone-containing products intended to treat alcohol or opioid addiction because of the severe consequence of naltrexone treatment failure [1].
That warning is about oral naltrexone, not about drinking alcohol.
Does this apply to compounded or research-use PT-141?
The label and its alcohol study cover Vyleesi, the FDA-approved bremelanotide product, a 1.75 mg subcutaneous autoinjector approved on June 21, 2019 [1][3]. It is approved for premenopausal women with acquired, generalized HSDD and is not indicated for men or postmenopausal women or to enhance sexual performance [1]. Products sold as PT-141 for compounding or research use are not Vyleesi and are not FDA-approved drugs [4][1].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Can I drink alcohol with PT-141?
Does alcohol make PT-141 nausea worse?
Does PT-141 raise blood pressure?
Can ondansetron prevent PT-141 nausea?
Does PT-141 interact with naltrexone for alcohol use disorder?
Is the alcohol study relevant to compounded PT-141?
References
Show all 4 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health. 2017;2(2):e108-e120.
- U.S. Food and Drug Administration.
- Official web page.